← Back to Search

Beta Blocker

Lidocaine for Pain

Phase 2 & 3
Waitlist Available
Led By Michael Norton, MD
Research Sponsored by Wake Forest University Health Sciences
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up following administration of a sub-induction dose of propofol, 0.5 mg/kg up to 50 mg, just prior to full induction
Awards & highlights

Study Summary

This trial tests whether esmolol and lidocaine can relieve propofol injection pain better than a placebo.

Eligible Conditions
  • Pain
  • Injection Site Reaction

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~following administration of a sub-induction dose of propofol, 0.5 mg/kg up to 50 mg, just prior to full induction
This trial's timeline: 3 weeks for screening, Varies for treatment, and following administration of a sub-induction dose of propofol, 0.5 mg/kg up to 50 mg, just prior to full induction for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Pain with propofol injection
Secondary outcome measures
Blood pressure
Heart rate
Oxygen saturation

Trial Design

3Treatment groups
Active Control
Placebo Group
Group I: LidocaineActive Control1 Intervention
1 mg/kg lidocaine to a max of 100 mg
Group II: EsmololActive Control1 Intervention
0.5 mg/kg esmolol to a max of 50 mg
Group III: PlaceboPlacebo Group1 Intervention
Saline water

Find a Location

Who is running the clinical trial?

Wake Forest University Health SciencesLead Sponsor
1,250 Previous Clinical Trials
1,007,145 Total Patients Enrolled
22 Trials studying Pain
2,415 Patients Enrolled for Pain
Michael Norton, MDPrincipal InvestigatorWake Forest University Health Sciences

Media Library

Esmolol (Beta Blocker) Clinical Trial Eligibility Overview. Trial Name: NCT04356352 — Phase 2 & 3
Pain Research Study Groups: Lidocaine, Esmolol, Placebo
Pain Clinical Trial 2023: Esmolol Highlights & Side Effects. Trial Name: NCT04356352 — Phase 2 & 3
Esmolol (Beta Blocker) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04356352 — Phase 2 & 3
~7 spots leftby Jun 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top